WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2006086456) COMBINATION OF ORGANIC COMPOUNDS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2006/086456    International Application No.:    PCT/US2006/004401
Publication Date: 17.08.2006 International Filing Date: 09.02.2006
IPC:
A61K 31/165 (2006.01), A61K 31/192 (2006.01), A61K 31/216 (2006.01), A61K 31/549 (2006.01), A61K 31/41 (2006.01), A61P 3/06 (2006.01), A61P 3/10 (2006.01), A61P 9/00 (2006.01), A61P 9/04 (2006.01), A61P 9/10 (2006.01), A61P 9/12 (2006.01), A61P 13/12 (2006.01), A61P 27/06 (2006.01)
Applicants: NOVARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH) (For All Designated States Except US).
NOVARTIS PHARMA GmbH [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT) (AT only).
WEBB, Randy Lee [US/US]; (US) (For US Only).
KSANDER, Gary Michael [US/US]; (US) (For US Only)
Inventors: WEBB, Randy Lee; (US).
KSANDER, Gary Michael; (US)
Agent: FERRAR0, Gregory D.; Corporate Intellectual Property, One Health Plaza, Bldg. 104, East Hanover, New Jersey 07936 (US)
Priority Data:
60/652,325 11.02.2005 US
60/655,102 22.02.2005 US
60/670,090 11.04.2005 US
Title (EN) COMBINATION OF ORGANIC COMPOUNDS
(FR) COMBINAISON DE COMPOSES ORGANIQUES
Abstract: front page image
(EN)The present invention relates to a combination comprising: (i) a renin inhibitor, or a pharmaceutically acceptable salt thereof; (ii) a neutral endopeptidase (NEP) inhibitor, or a pharmaceutically acceptable salt thereof; and optionally at least one therapeutic agent selected from the group consisting of (a) a diuretic, or a pharmaceutically acceptable salt thereof; and (b) an angiotensin II receptor blocker (ARB), or a pharmaceutically acceptable salt thereof; for the prevention of, delay the onset of and/or treatment of a disease or a condition mediated by angiotensin II and/or NEP activity, which method comprises administering to a warm-blooded animal, in need thereof, a therapeutically effective amount of a combination of the present invention.
(FR)La présente invention concerne une combinaison renfermant: (i) un inhibiteur de rénine, ou son sel pharmaceutiquement acceptable; (ii) un inhibiteur d'endopeptidase neutre (NEP) ou bien son sel pharmaceutiquement acceptable et facultativement au moins un agent thérapeutique choisi dans le groupe contenant: (a) un diurétique ou son sel pharmaceutiquement acceptable et (b) un bloqueur du récepteur d'angiotensine II (ARB) ou son sel pharmaceutiquement acceptable, pour la prévention, le retard de l'apparition ou le traitement d'une maladie ou d'un état médié par l'activité de l'angiotensine II et/ou d'EPN, ce procédé consistant à administrer à un animal à sang chaud, en situation de nécessité, une dose thérapeutique efficace d'une combinaison de la présente invention.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)